ATG-F与OKT3在肾移植术后急性排斥反应中的应用效果  

Clinical application efficacy of ATG-F and OKT3 on acute rejection following kidney transplantation

作　　者：常征[1] 郝俊文[1] 张爱民[1] 

机构地区：[1]济南军区总医院泌尿外科,山东济南250031

出　　处：《实用医药杂志》2016年第8期695-698,共4页Practical Journal of Medicine & Pharmacy

摘　　要：目的探讨应用注射用兔抗人T淋巴细胞多克隆抗体(ATG-F)及注射用抗人T细胞CD3鼠单克隆抗体(OKT3)治疗肾移植术后急性排斥反应的效果、安全性和不良反应等。方法笔者所在中心施行同种异体肾移植术后对于激素冲击治疗不敏感的急性排斥患者51例,分为两组,分别给予多克隆抗体ATG-F和单克隆抗体OKT3治疗,并对治疗效果、安全性和药物的不良反应等进行统计学分析。结果 ATG-F治疗28例,排斥反应逆转26例,治愈率89.3%;而OKT3抗组23例,排斥反应逆转16例,治愈率69.6%。两组结果间有显著性差异(P<0.05)。结论 OKT3和ATG-F同为抗淋巴细胞的抗体,但其针对难治性急性排斥反应的治疗效果,存在明显差异。ATG-F临床效果肯定,并且用量灵活,不良反应小。而OKT3治疗效果一般,则具有术后感染发生率增加,及白细胞减少等并发症。Objective To investigate the efficacy and reliability of ATG-F polyclonal antibody and OKT3 monoclonal antibody on acute rejection （AR） following kidney transplantation. Methods The 51 patients undergoing renal transplantation in author＇s center and wth acute rejection after renal transplant ation received methyprednisolone impulsing therapy but showed no effect. They were classified into two groups,and received ATG-F polyclonal antibody and OKT3 monoclonal antibody to prevent acute rejection respectively. Results The rejection reversal rates in OKT3 and ATG-F group were 69.6% and 83.9% ,respectively,there was significant difference （P〈0.05）. Conclusion As the therapeutic medicine to AR after transplantation,OKT3 and ATG-F can reverse AR all very well.It can rescue some of patients from losing allograft as a result of AR. But as kind of foreign protein,OKT3 can lead to many side effects such as increasing infection rate and leucopenia. Overall,the therapeutic effect of ATG-F is better than that of OKT3.

关 键 词：肾移植 急性排斥反应 抗体 

分 类 号：R692.5[医药卫生—泌尿科学]